Abstract
The epidermal growth factor receptor (EGFR) has an important role in the hyperplastic growth of tumor. Similar to tumor growth, rheumatoid arthritis (RA) synovium is hyperplastic, invasive, and expresses EGFR and its ligands. Activation of EGFR signaling is responsible for synovial fibroblast proliferation in RA. Furthermore, in addition to its role in proliferation, EGFR and its ligands can induce cytokine production of synovial fibroblasts during the pathogenesis of RA. Agents that target EGFR have yielded promising results in animal experiments involving RA, pharmacologic modulations targeting EGFR, or its ligands may give rise to new therapeutic approaches for RA. In this review article, we will discuss the biological features of EGFR and summarize recent advances regarding the role of EGFR in the pathogenesis and treatment of RA.
Similar content being viewed by others
References
Yuan FL, Li X, Lu WG, Li CW, Xu RS, Dong J (2011) IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets 15:529–534
Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP et al (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 397:131–135
Pickens SR, Chamberlain ND, Volin MV, Gonzalez M, Pope RM, Mandelin AM 2nd et al (2011) Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis 14:443–455
Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R et al (2011) Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 10:595–598
Semerano L, Clavel G, Assier E, Denys A, Boissier MC (2011) Blood vessels, a potential therapeutic target in rheumatoid arthritis? Jt Bone Spine 78:118–123
Szekanecz Z, Besenyei T, Paragh G, Koch AE (2009) Angiogenesis in rheumatoid arthritis. Autoimmunity 42:563–573
Bo GP, Zhou LN, He WF, Luo GX, Jia XF, Gan CJ et al (2009) Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clin Rheumatol 28:191–199
Larsen AK, Ouaret D, El Ouadrani K, Petitprez A (2011) Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131:80–90
Swanson CD, Akama-Garren EH, Stein EA, Petralia JD, Ruiz PJ, Edalati A et al (2012) Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. J Immunol 188:3513–3521
Shiozawa S, Shiozawa K, Tanaka Y, Morimoto I, Uchihashi M, Fujita T et al (1989) Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis. Ann Rheum Dis 48:820–828
Sumariwalla PF, Jin P, Zhang J, Ni I, Crawford D, Shepard HM et al (2008) Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. Arthritis Rheum 58:3071–3080
Gompels LL, Malik NM, Madden L, Jin P, Feldmann M, Shepard HM et al (2011) Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade. Arthritis Res Ther 13:R161
Yamane S, Ishida S, Hanamoto Y, Kumagai K, Masuda R, Tanaka K et al (2008) Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients. J Inflamm (Lond) 5:5
Kop EN, Kwakkenbos MJ, Teske GJ, Kraan MC, Smeets TJ, Stacey M et al (2005) Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum 52:442–450
Sullivan T, Benjamin CG, Kempf PW, Deeken JF (2010) Cetuximab in the treatment of rheumatoid arthritis. J Clin Rheumatol 16:32–33
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–1206
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ et al (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541–552
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775–787
Lemmon MA (2009) Ligand-induced ErbB receptor dimerization. Exp Cell Res 315:638–648
Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669–672
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
Marquardt H, Hunkapiller MW, Hood LE, Twardzik DR, De Larco JE, Stephenson JR et al (1983) Transforming growth factors produced by retrovirus-transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc Natl Acad Sci U S A 80:4684–4688
Shoyab M, McDonald VL, Bradley JG, Todaro GJ (1988) Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A 85:6528–6532
Margolis B, Li N, Koch A, Mohammadi M, Hurwitz DR, Zilberstein A et al (1990) The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma. EMBO J 9:4375–4380
Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K et al (1993) Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259:1604–1607
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31
Killock D (2012) Experimental arthritis: targeting EGFR to fight synovitis. Nat Rev Rheumatol 8:247
Young CL, Adamson TC 3rd, Vaughan JH, Fox RI (1984) Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 27:32–39
Lo SF, Wan L, Lin HC, Huang CM, Chen SY, Liu SC et al (2011) Association of rheumatoid arthritis risk with EGFR genetic polymorphisms in Taiwan’s Han Chinese population. Rheumatol Int 32(8):2301–2306
Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3–S8
Hallbeck AL, Walz TM, Briheim K, Wasteson A (2005) TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints. Scand J Rheumatol 34:204–211
Shepard HM, Brdlik CM, Schreiber H (2008) Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118:3574–3581
Acknowledgments
This work was supported by the China National Science Foundation grants No.30901526 and No. 81101372.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yuan, FL., Li, X., Lu, WG. et al. Epidermal growth factor receptor (EGFR) as a therapeutic target in rheumatoid arthritis. Clin Rheumatol 32, 289–292 (2013). https://doi.org/10.1007/s10067-012-2119-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2119-9